Azacitidine in the treatment of extramedullary relapse of AML after allogeneic hematopoietic cell transplantation

Bone Marrow Transplantation

Volumn 48, Issue 7, 2013, Pages 994-995

  Antar, A ^a   Otrock, Z K ^b   Kharfan Dabaja, M ^c   Salem, Z ^a   Aractingi, S ^d   Mohty, M ^e   Bazarbachi, A ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d HÔPITAL TENON   (France)

^e UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CLADRIBINE; CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ABDOMINAL MASS; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW EXAMINATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERABILITY; ERYTHEMA; FEMALE; GINGIVA HYPERTROPHY; GRANULOCYTIC SARCOMA; HUMAN; HUMAN TISSUE; LETTER; LEUKEMIA RELAPSE; LOW DRUG DOSE; MACULOPAPULAR RASH; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SALVAGE THERAPY; SKIN BIOPSY; SKIN NODULE; TREATMENT DURATION; TUMOR VOLUME;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MOUTH NEOPLASMS; RECURRENCE; SKIN NEOPLASMS;

EID: 84880223535     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.256     Document Type: Letter

References (10)

1. Bekassy AN, Hermans J, Gorin NC, Gratwohl A. Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1996; 17: 801-808.
2. Berthou C, Leglise MC, Herry A, Balcon D, Hardy E, Lessard M et al. Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia. Leukemia 1998; 12: 1676-1681.
3. Cunningham I. Extramedullary sites of leukemia relapse after transplant. Leuk Lymphoma 2006; 47: 1754-1767.
4. Frassoni F, Barrett AJ, Granena A, Ernst P, Garthon G, Kolb HJ et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases. Br J Haematol 1988; 70: 317-320.
5. Koc Y, Miller KB, Schenkein DP, Daoust P, Sprague K, Berkman E. Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation. Cancer 1999; 85: 608-615.
6. Lee KH, Lee JH, Choi SJ, Kim S, SeolM, Lee YS et al. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant 2003; 32: 835-842.
7. Savani BN, Mielke S, Reddy N, Goodman S, Jagasia M, Rezvani K. Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant 2009; 44: 769-777.
8. de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010; 116: 5420-5431.
9. Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012; 26: 381-389.
10. Serrao A, Loglisci G, Salaroli A, Zacheo I, Alimena G, Breccia M. Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization. Leuk Lymphoma (e-pub ahead of print